|1.||Chronic Kidney Failure (Chronic Renal Failure)
|3.||Renal Insufficiency (Renal Failure)
|4.||Body Weight (Weight, Body)
|1.||Salusky, Isidro B: 10 articles (05/2013 - 01/2003)|
|2.||Wesseling-Perry, Katherine: 6 articles (05/2013 - 10/2010)|
|3.||D'Haese, Patrick C: 6 articles (01/2011 - 03/2003)|
|4.||Coen, Giorgio: 6 articles (07/2006 - 02/2002)|
|5.||Goodman, William G: 6 articles (09/2005 - 01/2003)|
|6.||Jüppner, Harald: 5 articles (01/2012 - 01/2003)|
|7.||Monier-Faugere, Marie-Claude: 5 articles (06/2011 - 02/2008)|
|8.||Malluche, H H: 5 articles (10/2008 - 06/2000)|
|9.||De Broe, Marc E: 5 articles (08/2006 - 03/2003)|
|10.||Sardella, Daniela: 5 articles (07/2006 - 02/2002)|
|1.||Vitamin DFDA LinkGeneric
04/04/1975 - "Vitamin D analogues of high biological activity are probably useful in the treatment of renal osteodystrophy. "
01/01/1993 - "From these results we concluded that total PTX followed by massive administration of active vitamin D was effective in improving bone lesions and bone mineral density on patients with renal osteodystrophy."
06/20/1986 - "Recently, it has become well known that the clinical use of active vitamin D metabolites is effective in many patients with renal osteodystrophy. "
01/01/1992 - "The present study was carried out to assess a possible therapeutic role of this vitamin D metabolite in renal osteodystrophy. "
08/01/1977 - "The short duration of the protocol did not lend itself to the study of the effect of P control or the administration of vitamin D in the pathogenesis of renal osteodystrophy. "
01/01/1980 - "It is concluded that in the dose used 24,25(OH)2D3 alone is not an effective treatment for renal osteodystrophy."
06/01/2003 - "These studies assessed the efficacy of the 1,25(OH)2D3 analog, 19-Nor-1,25(OH)2D2 (19-Nor), in the prevention (protocol I) and treatment (protocol II) of SH and renal osteodystrophy in uremic rats. "
01/01/1980 - "The effect of 1,25 (OH)2D3 on bone mineralization: ultrastructural studies in patients with renal osteodystrophy."
05/01/2006 - "We observed the that latter analog, currently used to treat renal osteodystrophy, is more efficacious than 1,25(OH)2 D3 in inducing CYP3A9 in rat intestines. "
05/01/2000 - "Based on the above observations we suggest that the combined treatment with 1,25(OH)2D3 and 24,25(OH)2D3 markedly improves the morphologic and metabolic abnormalities of renal osteodystrophy."
09/17/1977 - "1-alpha-OHD3 was effective in reducing the biochemical and radiological abnormalities of renal osteodystrophy, but it should be used wtih care, and plasma calcium concentrations should be monitored."
11/01/2011 - "Dialysate calcium (Ca) concentration should be viewed as part of the integrated therapeutic regimen to control renal osteodystrophy and maintain normal mineral metabolism. "
01/01/2011 - "Dialysate calcium (Ca) concentration should be viewed as part of the integrated therapeutic regimen to control renal osteodystrophy and maintain normal mineral metabolism. "
03/01/2004 - "Aluminium-based agents are associated with bone toxicity, renal osteodystrophy and encephalopathy, and calcium-based agents increase the risk of hypercalcaemia and cardiovascular calcification. "
01/01/2002 - "Biological evolution of renal osteodystrophy after decreasing dialysate calcium from 1.75 to 1.6 mmol/l."
|4.||Calcitriol (Calcijex)FDA LinkGeneric
01/01/1992 - "Marked improvement in parameters of renal osteodystrophy with the use of intraperitoneal calcitriol."
11/01/2007 - "Calcitriol has long been used as the main therapy in renal osteodystrophy, but the efficacy of the oral route is not always as high as expected. "
01/01/1994 - "Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dose-comparable study."
03/01/2003 - "Repeated intervenous calcitriol administration is an established treatment for renal osteodystrophy. "
02/01/2002 - "Renal osteodystrophy (ROD) is a common and serious complication for uremic patients and patients are treated with 1,25-dihydroxyvitamin D3. "
01/01/1987 - "Furthermore, the effect of 1 alpha-hydroxyvitamin D3 treatment on renal osteodystrophy was evaluated by this method. "
01/01/1982 - "We have reservations about the ultimate value of long-term treatment with alfacalcidol in haemodialysed patients with renal osteodystrophy and urge caution in its use."
01/01/1982 - "Long-term experience of alfacalcidol in renal osteodystrophy."
06/01/1979 - "Effect of 1 alpha-hydroxyvitamin D3 in rats with experimental renal osteodystrophy."
01/01/1979 - "Two children suffering from renal osteodystrophy were treated by 1 alpha hydroxycholecalciferol (1 alpha OHD3) 1 microgr. "
|6.||Tetracycline (Achromycin)FDA LinkGeneric
11/01/2013 - "Transiliac bone biopsy and histomorphometry with double-labeled tetracycline or its derivatives remains the gold standard for diagnosis of renal osteodystrophy. "
04/01/2006 - "Bone biopsies and evaluation of mineralized bone sections after double tetracycline-labeling are currently considered the gold standard for diagnosis and classification of renal osteodystrophy. "
07/01/2000 - "Undecalcified bone biopsy with histomorphometric measurements and tetracycline labelling remains the gold standard for diagnosis of the different forms of renal osteodystrophy. "
03/01/2005 - "The diagnosis of osteoporosis in patients with CKD/ESRD must be done by first the exclusion of the other forms of renal osteodystrophy, by biochemical profiling or by double tetracycline-labeled bone biopsy; and the finding of low trabecular bone volume. "
03/01/2005 - "The diagnosis of osteoporosis in patients with CKD/ESRD must be done by first excluding other forms of renal osteodystrophy, through biochemical profiling or by double tetracycline-labeled bone biopsy and the finding of low trabecular bone volume. "
|7.||Parathyroid Hormone (Parathormone)IBA
06/01/2013 - "Switching between parathormone (PTH) assays: the impact on the diagnosis of renal osteodystrophy."
09/01/2009 - "A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations."
03/01/2009 - "New available treatments have contributed to move from the former treatment paradigm of renal osteodystrophy to CKD-MBD management, beyond mere control of parathyroid hormone (PTH) and trying to improve cardiovascular or survival outcomes. "
10/01/2008 - "Besides parathyroid hormone, biochemical parameters of bone turnover provide a moderate discrimination and prediction of bone turnover status only in patients with CKD Stage 5. Due to a large variability, they are of limited use in predicting the histomorphometric type of renal osteodystrophy. "
07/01/2008 - "Renal osteodystrophy patients have continuous bone loss due to chronically elevated parathyroid hormone (PTH). "
|8.||Biological Markers (Surrogate Marker)IBA
01/01/2004 - "In this study we investigated the value of biochemical markers of bone turnover in the diagnosis of renal osteodystrophy in dialysis patients. "
11/01/2013 - "Ultimately, the optimal diagnostic strategy for renal osteodystrophy may be a combination of multiple imaging techniques and biomarkers that are specific to each gender and race in CKD, with a goal of predicting fracture risk and optimizing therapy. "
06/01/2010 - "A combination of serum biochemical markers might predict underlying renal osteodystrophy better that would individual biochemical markers. "
06/01/2010 - "The importance of bone biomarkers in the diagnosis of renal osteodystrophy."
01/01/2004 - "Biochemical markers of bone turnover in the diagnosis of renal osteodystrophy in dialyzed children."
|9.||Cholecalciferol (Vitamin D3)FDA Link
01/01/1982 - "The studies have confirmed that 1,25-dihydroxy vitamin D3 is effective in controlling clinical, biochemical and histological features of renal osteodystrophy while 24,25-dihydroxy vitamin D3 did not have a useful therapeutic effect in the dose used."
11/01/1995 - "We assert that vitamin D3 treatment markedly reverses the development of renal osteodystrophy, and CT potentiates the effect of vitamin D3."
01/01/1982 - "Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy."
07/01/1980 - "Comparative therapeutic effects of vitamin D3 and its derivatives on experimental renal osteodystrophy."
03/03/1980 - "The present report describes our experiences in managing renal osteodystrophy by using vitamin D3 for 24 months. "
|10.||Calcifediol (Calcidiol)FDA Link
05/15/1978 - "The efficacy of calcifediol in renal osteodystrophy."
11/01/2008 - "Calcidiol deficiency has been underappreciated and deserves to be addressed in the treatment of patients with renal osteodystrophy. "
10/15/1982 - "Calcifediol for renal osteodystrophy."
05/01/1982 - "25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity."
11/01/1979 - "25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients."
|1.||Continuous Ambulatory Peritoneal Dialysis (CAPD)
11/01/1983 - "Although CAPD and appropriate therapy benefited most patients with renal osteodystrophy, the benefits were not uniform, and bone lesions deteriorated in some."
06/01/2000 - "The aim of the study was to evaluate the prevalence of renal osteodystrophy types in children undergoing haemodialysis and continuous ambulatory peritoneal dialysis and to assess the usefulness of biochemical parameters in diagnosis of renal osteodystrophy. "
01/01/1988 - "Renal osteodystrophy in children on CAPD: a prospective trial of 1-alpha-hydroxycholecalciferol therapy."
01/01/1980 - "In this report we will present the results of our radiological and biochemical studies of renal osteodystrophy in 28 patients who have been on CAPD from 6 to 23 months."
02/01/2000 - "Spectrum of renal osteodystrophy in children on continuous ambulatory peritoneal dialysis."
|2.||Renal Dialysis (Hemodialysis)
12/01/2010 - "In a retrospective observational study, we examined PTH variability parameters in a group of hemodialysis patients as independent risk factors for high vs. low turnover osteopathy, and investigated their usefulness with respect to commonly used markers of renal osteodystrophy. "
07/01/2000 - "The aim of our study was to determine the prevalence of the different forms of renal osteodystrophy in our patients in hemodialysis. "
01/01/1999 - "Some densitometric studies in hemodialysis patients have already been published but their results differ in prevalence and intensity of renal osteodystrophy. "
03/01/1995 - "[A study on the relative factors for secondary parathyroidosis and renal osteodystrophy in long-term hemodialysis patients]."
05/09/1982 - "[Histologic and histomorphometric study of bone biopsy material from patients with renal osteodystrophy undergoing hemodialysis]."
|3.||Transplantation (Transplant Recipients)
12/01/2011 - "Newer imaging techniques, including computed tomography (quantitative CT (QCT), peripheral QCT (pQCT), high resolution pQCT (HR-pQCT) and magnetic resonance imaging (MRI)), which provide volumetric assessments of bone density and are able to discriminate bone microarchitecture, show promise in the assessment of bone strength; however, future studies are needed to define the value of these techniques in the diagnosis and treatment of renal osteodystrophy in pediatric renal transplant recipients."
03/01/2005 - "While BMD remained stable or improved between 3 and 12 months after transplantation, the decrease in BUA seems to reflect a continuing change in bone structure in this population with preexistent renal osteodystrophy."
01/01/2010 - "This loss of bone results from a combination of factors that include pre-existing renal osteodystrophy, immunosuppressive therapy, and the effects of chronically reduced renal function after transplantation. "
12/01/2007 - "Nevertheless, renal osteodystrophy persists in many transplant recipients. "
10/01/1984 - "Renal osteodystrophy in renal transplant recipients."
10/01/2005 - "Data is available on complication rates and some important outcome measures of parathyroidectomy, but the efficacy of calcimimetics to influence patient-based endpoints such as cardiovascular mortality and renal osteodystrophy has not been established. "
02/01/1996 - "Although the short-term outcome of total parathyroidectomy combined with autotransplantation in cases of renal osteodystrophy has been reported by many investigators, few studies have been made on the long-term outcome of this surgical technique. "
01/01/1993 - "This study investigated the changes of bone lesions after parathyroidectomy (PTX) in patients with renal osteodystrophy. "
01/01/1993 - "[A clinical multivariate study on bone change after parathyroidectomy in patients with renal osteodystrophy]."
06/01/1969 - "Physiologic studies in renal osteodystrophy treated by subtotal parathyroidectomy."
05/01/2010 - "Renal transplantation is the definitive treatment for many metabolic abnormalities of uremic patients, although it is only partially effective for renal osteodystrophy, which may interact with posttransplant renal osteopathy. "
12/01/2007 - "We concluded that renal osteodystrophy, especially forms with high bone turnover, persisted in many patients after successful renal transplantation. "
12/01/2007 - "Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients."
05/01/2004 - "After renal transplantation, renal osteodystrophy generally improves but bone mineral density (BMD) often worsens. "
03/01/2004 - "It derives in a significant part from pre-existing renal osteodystrophy, but it is aggravated by factors emerging after renal transplantation. "